220 related articles for article (PubMed ID: 21823889)
21. Crizotinib in the treatment of non-small-cell lung cancer.
Forde PM; Rudin CM
Expert Opin Pharmacother; 2012 Jun; 13(8):1195-201. PubMed ID: 22594847
[TBL] [Abstract][Full Text] [Related]
22. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.
Solomon B; Wilner KD; Shaw AT
Clin Pharmacol Ther; 2014 Jan; 95(1):15-23. PubMed ID: 24091716
[TBL] [Abstract][Full Text] [Related]
23. ALK in lung cancer: past, present, and future.
Shaw AT; Engelman JA
J Clin Oncol; 2013 Mar; 31(8):1105-11. PubMed ID: 23401436
[TBL] [Abstract][Full Text] [Related]
24. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.
Camidge DR; Theodoro M; Maxson DA; Skokan M; O'Brien T; Lu X; Doebele RC; Barón AE; Varella-Garcia M
Cancer; 2012 Sep; 118(18):4486-94. PubMed ID: 22282074
[TBL] [Abstract][Full Text] [Related]
25. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer.
Pailler E; Adam J; Barthélémy A; Oulhen M; Auger N; Valent A; Borget I; Planchard D; Taylor M; André F; Soria JC; Vielh P; Besse B; Farace F
J Clin Oncol; 2013 Jun; 31(18):2273-81. PubMed ID: 23669222
[TBL] [Abstract][Full Text] [Related]
26. Heart rate decrease during crizotinib treatment and potential correlation to clinical response.
Ou SH; Tong WP; Azada M; Siwak-Tapp C; Dy J; Stiber JA
Cancer; 2013 Jun; 119(11):1969-75. PubMed ID: 23505007
[TBL] [Abstract][Full Text] [Related]
27. New strategies for treatment of ALK-rearranged non-small cell lung cancers.
Sasaki T; Jänne PA
Clin Cancer Res; 2011 Dec; 17(23):7213-8. PubMed ID: 22010214
[TBL] [Abstract][Full Text] [Related]
28. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.
Roskoski R
Expert Opin Drug Discov; 2013 Sep; 8(9):1165-79. PubMed ID: 23805942
[TBL] [Abstract][Full Text] [Related]
29. Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
Kijima T; Takeuchi K; Tetsumoto S; Shimada K; Takahashi R; Hirata H; Nagatomo I; Hoshino S; Takeda Y; Kida H; Goya S; Tachibana I; Kawase I
Cancer Sci; 2011 Aug; 102(8):1602-4. PubMed ID: 21767331
[TBL] [Abstract][Full Text] [Related]
30. Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.
Tiseo M; Gelsomino F; Bartolotti M; Bordi P; Bersanelli M; Rossi G; Ardizzoni A
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1677-87. PubMed ID: 22050016
[TBL] [Abstract][Full Text] [Related]
31. Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options.
Lazzari C; Spitaleri G; Catania C; Barberis M; Noberasco C; Santarpia M; Delmonte A; Toffalorio F; Conforti F; De Pas TM
Crit Rev Oncol Hematol; 2014 Mar; 89(3):358-65. PubMed ID: 24156959
[TBL] [Abstract][Full Text] [Related]
32. Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.
de Castro-Carpeño J; Perona R; Belda-Iniesta C
Clin Transl Oncol; 2011 Nov; 13(11):774-9. PubMed ID: 22082640
[TBL] [Abstract][Full Text] [Related]
33. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ
J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824
[No Abstract] [Full Text] [Related]
34. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.
Yi ES; Chung JH; Kulig K; Kerr KM
Mol Diagn Ther; 2012 Jun; 16(3):143-50. PubMed ID: 22506598
[TBL] [Abstract][Full Text] [Related]
35. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
Lee JA; Bubendorf L; Stahel R; Peters S
Expert Rev Anticancer Ther; 2013 May; 13(5):625-36. PubMed ID: 23617353
[TBL] [Abstract][Full Text] [Related]
36. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
Camidge DR; Bang YJ; Kwak EL; Iafrate AJ; Varella-Garcia M; Fox SB; Riely GJ; Solomon B; Ou SH; Kim DW; Salgia R; Fidias P; Engelman JA; Gandhi L; Jänne PA; Costa DB; Shapiro GI; Lorusso P; Ruffner K; Stephenson P; Tang Y; Wilner K; Clark JW; Shaw AT
Lancet Oncol; 2012 Oct; 13(10):1011-9. PubMed ID: 22954507
[TBL] [Abstract][Full Text] [Related]
37. Experience in integrating ALK testing and crizotinib into the routine treatment of patients with non-small cell lung cancer.
Gautschi O; Schefer H; Riklin C; Strobel K; Diebold J
Onkologie; 2013; 36(6):342-7. PubMed ID: 23774148
[TBL] [Abstract][Full Text] [Related]
38. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.
Kaneda H; Okamoto I; Nakagawa K
J Thorac Oncol; 2013 Apr; 8(4):e32-3. PubMed ID: 23486271
[No Abstract] [Full Text] [Related]
39. [Management of crizotinib, a new individualized treatment].
Fallet V; Toper C; Antoine M; Cadranel J; Wislez M
Bull Cancer; 2012; 99(7-8):787-91. PubMed ID: 22713522
[TBL] [Abstract][Full Text] [Related]
40. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy.
Camidge DR; Skokan M; Kiatsimkul P; Helfrich B; Lu X; Barón AE; Schulte N; Maxson D; Aisner DL; Franklin WA; Doebele RC; Varella-Garcia M
Cancer; 2013 Nov; 119(22):3968-75. PubMed ID: 24022839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
